Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
Source: SeekingAlpha
2026-05-09 04:02:52 ET
More on ALX Oncology
- ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
- ALX Oncology Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation
- ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones
- ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing
- Seeking Alpha’s Quant Rating on ALX Oncology
Read the full article on Seeking Alpha
For further details see:
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
ALX Oncology Holdings Inc.
NASDAQ: ALXO
ALXO Trading
-11.21% G/L:
$1.545 Last:
552,741 Volume:
$1.58 Open:
ALXO Latest News
June 01, 2026 08:00:00 am
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
May 08, 2026 08:00:00 am
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALXO Stock Data
$136,900,453
32,964,545
2.6%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
